Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT5B | Q4FZB7 | 2/20 | 0.57 |
| ▸ | KMT5C | Q86Y97 | 2/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 13/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873010 | 1.00 | KMT5B (0.57) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6867330 | 0.88 | KMT5B (0.61) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6867326 | 0.88 | KMT5B (0.61) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6872817 | 0.88 | KMT5B (0.57) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6872815 | 0.88 | KMT5B (0.57) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6870119 | 0.87 | KMT5B (0.58) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6870115 | 0.87 | KMT5B (0.58) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6865817 | 0.86 | KMT5B (0.66) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6865821 | 0.86 | KMT5B (0.66) | KMT5BKMT5CNSD2CYP2D6CYP2C19 | |
| SCHEMBL6872061 | 0.86 | KMT5B (0.57) | KMT5BKMT5CNSD2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | claimed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | claimed |
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | KMT5B 1214/4885KMT5C 1285/4885NSD2 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.